Literature DB >> 36149495

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update.

Gabriel Rinnerthaler1, Christian Singer2, Edgar Petru3, Daniel Egle4, Andreas Petzer5, Ursula Pluschnig6, Simon Peter Gampenrieder1, Georg Pfeiler2, Michael Gnant7, Birgit Grünberger8, Peter Krippl9, Kathrin Strasser-Weippl10, Christoph Suppan11, Christine Brunner4, Renate Pusch5, Margit Sandholzer12, Marija Balic13, Rupert Bartsch14.   

Abstract

In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those patients. For this consensus paper a total of eight scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.
© 2022. The Author(s).

Entities:  

Keywords:  Advanced breast cancer; Antibody-drug conjugates; Erbb2; Systemic therapy; Tyrosin kinase inhibitors

Year:  2022        PMID： 36149495     DOI： 10.1007/s00508-022-02082-3

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   2.275


  23 in total

1.  Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

Authors:  William J Gradishar; Benjamin O Anderson; Jame Abraham; Rebecca Aft; Doreen Agnese; Kimberly H Allison; Sarah L Blair; Harold J Burstein; Chau Dang; Anthony D Elias; Sharon H Giordano; Matthew P Goetz; Lori J Goldstein; Steven J Isakoff; Jairam Krishnamurthy; Janice Lyons; P Kelly Marcom; Jennifer Matro; Ingrid A Mayer; Meena S Moran; Joanne Mortimer; Ruth M O'Regan; Sameer A Patel; Lori J Pierce; Hope S Rugo; Amy Sitapati; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; Erica M Stringer-Reasor; Melinda L Telli; John H Ward; Jessica S Young; Jennifer L Burns; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2020-04       Impact factor: 11.908

Review 2.  Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Authors:  Ana Catarina Pinto; Felipe Ades; Evandro de Azambuja; Martine Piccart-Gebhart
Journal:  Breast       Date:  2013-08       Impact factor: 4.380

3.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Authors:  Rashmi K Murthy; Sherene Loi; Alicia Okines; Elisavet Paplomata; Erika Hamilton; Sara A Hurvitz; Nancy U Lin; Virginia Borges; Vandana Abramson; Carey Anders; Philippe L Bedard; Mafalda Oliveira; Erik Jakobsen; Thomas Bachelot; Shlomit S Shachar; Volkmar Müller; Sofia Braga; Francois P Duhoux; Richard Greil; David Cameron; Lisa A Carey; Giuseppe Curigliano; Karen Gelmon; Gabriel Hortobagyi; Ian Krop; Sibylle Loibl; Mark Pegram; Dennis Slamon; M Corinna Palanca-Wessels; Luke Walker; Wentao Feng; Eric P Winer
Journal:  N Engl J Med       Date:  2019-12-11       Impact factor: 91.245

4.  Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.

Authors:  G Curigliano; V Mueller; V Borges; E Hamilton; S Hurvitz; S Loi; R Murthy; A Okines; E Paplomata; D Cameron; L A Carey; K Gelmon; G N Hortobagyi; I Krop; S Loibl; M Pegram; D Slamon; J Ramos; W Feng; E Winer
Journal:  Ann Oncol       Date:  2021-12-23       Impact factor: 32.976

5.  Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

Authors:  Jean-Marc Extra; Eric C Antoine; Anne Vincent-Salomon; Thierry Delozier; Pierre Kerbrat; Anne Bethune-Volters; Jean-Paul Guastalla; Marc Spielmann; Louis Mauriac; Jean-Louis Misset; Daniel Serin; Mario Campone; Christophe Hebert; Céline Remblier; Loïc Bergougnoux; Frank Campana; Moïse Namer
Journal:  Oncologist       Date:  2010-07-29

6.  Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.

Authors:  Rupert Bartsch; Simon Peter Gampenrieder; Gabriel Rinnerthaler; Edgar Petru; Daniel Egle; Andreas Petzer; Marija Balic; Ursula Pluschnig; Thamer Sliwa; Christian Singer
Journal:  Wien Klin Wochenschr       Date:  2022-01-28       Impact factor: 1.704

7.  Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).

Authors:  Volkmar Mueller; Andrew Wardley; Elisavet Paplomata; Erika Hamilton; Amelia Zelnak; Louis Fehrenbacher; Erik Jakobsen; Elsa Curtit; Frances Boyle; Eva Harder Brix; Andrew Brenner; Laurence Crouzet; Cristiano Ferrario; Montserrat Muñoz-Mateu; Hendrik-Tobias Arkenau; Nayyer Iqbal; Sramila Aithal; Margaret Block; Soeren Cold; Mathilde Cancel; Olwen Hahn; Teja Poosarla; Erica Stringer-Reasor; Marco Colleoni; David Cameron; Giuseppe Curigliano; Muriel Siadak; Kendra DeBusk; Jorge Ramos; Wentao Feng; Karen Gelmon
Journal:  Eur J Cancer       Date:  2021-06-29       Impact factor: 9.162

8.  Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.

Authors:  Nancy U Lin; Virginia Borges; Carey Anders; Rashmi K Murthy; Elisavet Paplomata; Erika Hamilton; Sara Hurvitz; Sherene Loi; Alicia Okines; Vandana Abramson; Philippe L Bedard; Mafalda Oliveira; Volkmar Mueller; Amelia Zelnak; Michael P DiGiovanna; Thomas Bachelot; A Jo Chien; Ruth O'Regan; Andrew Wardley; Alison Conlin; David Cameron; Lisa Carey; Giuseppe Curigliano; Karen Gelmon; Sibylle Loibl; JoAl Mayor; Suzanne McGoldrick; Xuebei An; Eric P Winer
Journal:  J Clin Oncol       Date:  2020-05-29       Impact factor: 44.544

9.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

Authors:  F Cardoso; S Paluch-Shimon; E Senkus; G Curigliano; M S Aapro; F André; C H Barrios; J Bergh; G S Bhattacharyya; L Biganzoli; F Boyle; M-J Cardoso; L A Carey; J Cortés; N S El Saghir; M Elzayat; A Eniu; L Fallowfield; P A Francis; K Gelmon; J Gligorov; R Haidinger; N Harbeck; X Hu; B Kaufman; R Kaur; B E Kiely; S-B Kim; N U Lin; S A Mertz; S Neciosup; B V Offersen; S Ohno; O Pagani; A Prat; F Penault-Llorca; H S Rugo; G W Sledge; C Thomssen; D A Vorobiof; T Wiseman; B Xu; L Norton; A Costa; E P Winer
Journal:  Ann Oncol       Date:  2020-09-23       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.